Cullinan Therapeutics (Nasdaq:CGEM) - 주가, 뉴스 및 분석

이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

CGEM 주식 개요

바이오 제약 회사인 컬리넌 테라퓨틱스는 미국 내 암 환자를 위한 종양 치료법 개발에 주력하는 회사입니다.

CGEM 기본 분석
눈송이 점수
가치 평가	2/6
미래 성장	2/6
과거 실적	0/6
재무 상태	6/6
배당금	0/6

보상

수익은 연간 54.3% 증가할 것으로 예상됩니다.

분석가들은 주가가 96.3% 상승할 것이라는 데 동의합니다.

위험 분석

수익은 향후 3년간 연평균 9.7% 씩 감소할 것으로 예상됩니다.

수익이 1백만 달러 미만인 경우 ( $0 )

현재 수익성이 없으며 향후 3년 동안 수익을 낼 것으로 예상되지 않습니다.

지난 1년 동안 주주가 희석되었습니다.

+ 1 더 많은 위험

Cullinan Therapeutics, Inc. 경쟁사

Sage Therapeutics

NasdaqGM:SAGE

US$647.0m

Corbus Pharmaceuticals Holdings

NasdaqCM:CRBP

US$456.0m

Lexicon Pharmaceuticals

NasdaqGS:LXRX

US$632.6m

Cogent Biosciences

NasdaqGS:COGT

US$914.1m

가격 내역 및 성능

다음에 대한 모든 사상 최고가, 변동 및 가격 하락 요약 Cullinan Therapeutics
과거 주가
현재 주가	US$17.43
52주 최고치	US$30.19
52주 최저치	US$7.64
베타	-0.057
11개월 변경	-24.68%
3개월 변경 사항	5.13%
1년 변경 사항	40.34%
33년 변화	-36.62%
5년 변화	n/a
IPO 이후 변화	-41.73%

최근 뉴스 및 업데이트

Checking Into Cullinan Therapeutics

Jun 09

Recent updates

Checking Into Cullinan Therapeutics

Jun 09

Companies Like Cullinan Therapeutics (NASDAQ:CGEM) Are In A Position To Invest In Growth

Apr 23

Companies Like Cullinan Oncology (NASDAQ:CGEM) Are In A Position To Invest In Growth

Jun 24

Here's Why We're Not Too Worried About Cullinan Oncology's (NASDAQ:CGEM) Cash Burn Situation

Mar 05

Companies Like Cullinan Oncology (NASDAQ:CGEM) Are In A Position To Invest In Growth

Oct 08

Cullinan Oncology: Hub-And-Spoke Business Model For Drug Development

Jun 30

Cullinan Oncology (CGEM) Presents At 2021 ASCO Annual Virtual Meeting - Slideshow

Jun 05

Cullinan initiated Buy at H.C. Wainwright on pipeline strength

Feb 02

주주 수익률

	CGEM	US Biotechs	US 마켓
7D	-7.7%	-1.3%	0.4%
1Y	40.3%	7.7%	22.9%

수익률 대 산업: CGEM 지난 1년 동안 6.7 %를 반환한 US Biotechs 산업을 초과했습니다.

수익률 대 시장: CGEM 지난 1년 동안 23.3 %를 반환한 US 시장을 초과했습니다.

가격 변동성

Is CGEM's price volatile compared to industry and market?
CGEM volatility
CGEM Average Weekly Movement	13.6%
Biotechs Industry Average Movement	10.5%
Market Average Movement	5.7%
10% most volatile stocks in US Market	15.5%
10% least volatile stocks in US Market	2.9%

안정적인 주가: CGEM 의 주가는 지난 3개월 동안 변동성이 심했습니다.

시간에 따른 변동성: CGEM 의 주간 변동성( 14% )은 지난 1년 동안 안정적이었지만 여전히 US 의 75%보다 높습니다. 주식.

회사 소개

설립	직원	CEO	웹사이트
2016	85	Nadim Ahmed	cullinantherapeutics.com

바이오 제약 회사인 컬리넌 테라퓨틱스는 미국 내 암 환자를 위한 종양 치료법 개발에 주력하고 있습니다. 이 회사의 주요 프로그램은 고형 종양 치료를 위한 임상 1상 시험 중인 단일 클론 항체 CLN-619로 구성되어 있습니다. 또한 급성 골수성 백혈병 또는 골수형성이상증후군 치료를 위한 임상 1상 시험 중인 인간화 이중특이성 항체 CLN-049, 다발성 고형암 치료를 위한 임상 1상 시험 중인 인간 이중특이성 면역 활성화제 CLN-418, 비소세포폐암 환자 치료를 위한 생체 이용 가능 소분자 지팔러티닙도 개발 포트폴리오에 포함돼 있습니다.

Cullinan Therapeutics, Inc. 기본 사항 요약

Cullinan Therapeutics 의 수익과 매출은 시가총액과 어떻게 비교하나요?
CGEM 기본 통계
시가총액	US$1.01b
수익(TTM)	-US$132.35m
수익(TTM)	n/a

0.0x

P/S 비율

-7.6x

P/E 비율

CGEM 주가가 과대평가되어 있나요?

공정 가치 및 가치 분석 보기

수익 및 수익

최신 수익 보고서의 주요 수익성 통계(TTM)
CGEM 손익 계산서(TTM)
수익	US$0
수익 비용	US$0
총 이익	US$0
기타 비용	US$132.35m
수익	-US$132.35m

최근 보고된 수익

Mar 31, 2024

다음 수익 날짜

n/a

주당 순이익(EPS)	-2.30
총 마진	0.00%
순이익 마진	0.00%
부채/자본 비율	0%

CGEM 의 장기적인 성과는 어땠나요?

과거 실적 및 비교 보기

CGEM 주식 개요

보상

위험 분석

Cullinan Therapeutics, Inc. 경쟁사

NasdaqGM:SAGE

US$647.0m

NasdaqCM:CRBP

US$456.0m

NasdaqGS:LXRX

US$632.6m

NasdaqGS:COGT

US$914.1m

가격 내역 및 성능

최근 뉴스 및 업데이트

Independent Director exercised options to buy US$402k worth of stock.

Checking Into Cullinan Therapeutics

Cullinan Therapeutics, Inc. Announces Positive Initial Data from Pivotal Phase 2b Rezil1 Study of Zipalertinib

Independent Director exercised options to buy US$2.4m worth of stock.

Consensus EPS estimates upgraded to US$3.01 loss

Cullinan Therapeutics, Inc., Annual General Meeting, Jun 26, 2024

Recent updates

Independent Director exercised options to buy US$402k worth of stock.

Checking Into Cullinan Therapeutics

Cullinan Therapeutics, Inc. Announces Positive Initial Data from Pivotal Phase 2b Rezil1 Study of Zipalertinib

Independent Director exercised options to buy US$2.4m worth of stock.

Consensus EPS estimates upgraded to US$3.01 loss

Cullinan Therapeutics, Inc., Annual General Meeting, Jun 26, 2024

Cullinan Therapeutics, Inc. Announces Board Changes

Chief Scientific Officer notifies of intention to sell stock

Consensus revenue estimates increase by 19%

Cullinan Therapeutics, Inc Appoints Mary Kay Fenton as Chief Financial Officer

Companies Like Cullinan Therapeutics (NASDAQ:CGEM) Are In A Position To Invest In Growth

Price target increased by 13% to US$28.71

Cullinan Oncology, Inc. announced that it expects to receive $280.000024 million in funding

Cullinan Oncology, Inc. Announces Resignation of Jeff Trigilio as Chief Financial Officer , Effective from March 29, 2024

Cullinan Oncology, Inc. Announces Resignation of Jeff Trigilio as Chief Financial Officer , Effective from March 29, 2024

Chief Business Officer notifies of intention to sell stock

New minor risk - Shareholder dilution

Cullinan Oncology, Inc. Announces First Patient Dosed in Phase 1 Trial Evaluating CLN-617, a Novel Fusion Protein Uniquely Harnessing Both IL-2 and IL-12 Cytokines

Cullinan Oncology, Inc. to Present Data Demonstrating Progress Across Its Broad Immunotherapy-Pipeline at SITC 2023

Price target decreased by 11% to US$25.25

New minor risk - Profitability

Taiho Oncology, Inc., Taiho Pharmaceutical Co., Ltd., and Cullinan Oncology, Inc. Announces the Launch of the REZILIENT3 Trial

Investor sentiment improves as stock rises 17%

High number of new and inexperienced directors

Chief Development Officer notifies of intention to sell stock

Investor sentiment improves as stock rises 16%

Cullinan Oncology, Inc. Announces First Clinical Data from its Phase 1 Study of CLN-619 in Patients with Advanced Solid Tumors

Cullinan Oncology, Inc. Announces U.S. FDA Clearance of Investigational New Drug Application for CLN-978, Novel T-Cell Engager for Treatment of Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma

Investor sentiment deteriorated over the past week

Chief Development Officer notifies of intention to sell stock

Price target decreased to US$34.00

Cullinan Oncology Appoints of David P. Ryan to Its Board of Directors

Investor sentiment improved over the past week

Cullinan Oncology: Modality-Agnostic Approach To Yield Fruit In Coming Years

Cullinan Oncology: One Of The Leaders In Cancer Treatment Development

Cullinan Oncology grants stock options for 125.7K shares

Cullinan Oncology, Inc. Appoints Jacquelyn Sumer as Chief Legal Officer

Insider recently sold US$712k worth of stock

Chief Business Officer notifies of intention to sell stock

Chief Business Officer notifies of intention to sell stock

Cullinan Oncology, Inc.(NasdaqGS:CGEM) dropped from Russell 2000 Growth Index

Insider recently sold US$1.3m worth of stock

Taiho Pharmaceutical Co., Ltd. completed the acquisition of Cullinan Pearl Corp from Cullinan Oncology, Inc. (NasdaqGS:CGEM).

Companies Like Cullinan Oncology (NASDAQ:CGEM) Are In A Position To Invest In Growth

President recently bought US$100k worth of stock

Insider recently sold US$4.0m worth of stock

Price target decreased to US$39.25

Forecast to breakeven in 2022

Taiho Pharmaceutical Co., Ltd. entered into a Share Purchase Agreement to acquire Cullinan Pearl Corp from Cullinan Oncology, Inc. (NasdaqGS:CGEM) for approximately $400 million.

Cullinan Oncology, Inc., Annual General Meeting, Jun 22, 2022

Cullinan Oncology Announces Clinical and Regulatory Update for CLN-081 in NSCLC EGFR Exon 20 Patients

Cullinan Oncology, Inc. to Present Data Demonstrating Breadth and Progress of Its Immuno-Oncology Portfolio At American Association for Cancer Research 2022

Here's Why We're Not Too Worried About Cullinan Oncology's (NASDAQ:CGEM) Cash Burn Situation

Cullinan Oncology, Inc. Announces Management Appointments

Price target decreased to US$47.75

U.S. Food and Drug Administration Grants Breakthrough Therapy Designation for Cln-081 for the Treatment of Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer

Strategic Advisor notifies of intention to sell stock

Cullinan Oncology, Inc. Announces Updated Phase 1/2a Data for CLN-081 in NSCLC EGFR Exon 20 Patients

CFO & Treasurer exercised options and sold US$166k worth of stock